F-1/A: Medicus Pharma Eyes Nasdaq Listing with Proposed Unit Offering

Medicus Pharma is seeking to raise capital and list on the Nasdaq through an offering of 500,000 units, each comprising a common share and a warrant.

Summary

• Medicus Pharma Ltd. is planning a unit offering consisting of 500,000 common shares and 500,000 warrants.
• Each warrant allows the holder to purchase one common share at an exercise price equal to the unit offering price and expires five years from the issuance date.
• The company has applied to list its common shares and warrants on the Nasdaq Capital Market under the symbols 'MDCX' and 'MDCXW', respectively.
• The offering is contingent upon Nasdaq approval of the listing.
• Medicus Pharma intends to use the net proceeds to fund a Phase 2 clinical trial for SkinJectTM, a treatment for basal cell carcinoma.
• The company may also use proceeds to expand the trial to a pivotal study or to cover other non-melanoma skin diseases.
• Maxim Group LLC is acting as the sole book-running manager for the offering, and Brookline Capital Markets is acting as co-manager.
• The closing price of Medicus Pharma's common shares on the TSX Venture Exchange on October 11, 2024, was C$3.45, equivalent to approximately $2.51, or C$6.90 and $5.01 after giving effect to the Share Consolidation.
• The initial public offering price for the Units will be determined based on the bookbuilding process and is expected to be at or close to the closing price of our common shares on the TSXV on the most recent trading date prior to the pricing date of the offering.
• For purposes of this prospectus we have assumed an initial public offering price of $5.01, which is the U.S. dollar equivalent of the closing price of our common shares on the TSXV on October 11, after giving effect to the Share Consolidation.
• The underwriters have a 45-day option to purchase up to an additional 75,000 common shares and/or warrants to cover overallotments.
• Following the offering, there will be 11,346,780 common shares outstanding, or 11,421,780 if the underwriters' overallotment option is exercised in full.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is pursuing a Nasdaq listing and has a promising technology, but it also faces significant risks and challenges typical of early-stage biotech companies.

Positives

• The offering will provide capital to advance the clinical development of SkinJectTM.
• A Nasdaq listing could increase the company's visibility and access to capital.
• The warrants provide potential future funding for the company if exercised.
• The company has a senior management team with deep experience in medicine and pharmaceutical science as well as a proven track record in business development and entrepreneurship.
• The company has successfully completed a Phase 1 study of the Product.
• The company has potential to treat a range of other common non-melanoma skin cancers as well as pre-cancerous lesions.

Negatives

• The offering is contingent on Nasdaq listing approval.
• The company has a limited operating history and no history of earnings.
• The company has an accumulated deficit of approximately US$24.8 million as of June 30, 2024.
• The company has a novel technology with uncertain market acceptance.
• The company will be treated as a foreign private issuer and, as a result, will not be subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.

Risks

• Failure to obtain Nasdaq listing approval would prevent the offering.
• The company's limited operating history and lack of earnings create uncertainty.
• Clinical trials may not be successful, and regulatory approval may not be obtained.
• The company may require additional financing in the future, which may not be available.
• The company operates in a highly competitive industry.
• The company relies on key personnel.
• The company may not be able to successfully execute its business strategy.
• The company may be responsible for corruption and anti-bribery law violations.
• The company is subject to foreign exchange risks.
• The company is subject to taxation risks and changing rules by different tax authorities.
• The company is subject to a number of risks and hazards, of which not all of them may be sufficiently insured for.
• The company is subject to risks related to health epidemics and pandemics.
• Coverage and reimbursement may be limited or unavailable in certain market segments for the Product, which could make it difficult for us to sell the Product profitably.
• Our relationship with healthcare providers and physicians and third-party payors will be subject to applicable antikickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
• Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.
• We may experience fluctuations in market value.
• Our securities could be subject to large price and volume volatility.
• We will need to raise additional financing in the future which may dilute our share capital.
• We have no history of dividends.
• Future sales of our common shares by our existing shareholders could cause our share price and our warrant price to decline.
• We may issue, without shareholder approval, preferred shares that have rights and preferences potentially superior to those of our common shares.
• If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common shares, the price of our common shares and our warrants could decline.
• An investment in this offering may result in uncertain or adverse U.S. federal income tax consequences.
• There is no liquid public market for our common shares in the United States and there is no existing public market for our warrants, and, in each case, we do not know whether one will develop to provide you with adequate liquidity.
• If our share price or the price of our warrants fluctuates after this offering, you could lose a significant part of your investment.
• As a result of becoming a public company in the United States, we will become subject to additional regulatory compliance requirements, including Section 404 of the Sarbanes-Oxley Act, and if we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud.
• If we are unable for any reason to meet the continued listing requirements of the U.S. Exchange or the TSXV, such action or inaction could result in a delisting of our common shares and our warrants, as applicable.
• There is a risk that we will fail to maintain an effective system of internal controls and our ability to produce timely and accurate financial statements or comply with applicable regulations could be adversely affected.
• We will incur increased costs as a result of our operation as a dual U.S.-Canadian public company, and our management will be required to devote substantial time and resources to employing new compliance initiatives in order to comport with the regulatory requirements applicable to public companies.
• We may be subject to securities litigation, which is expensive and could divert management attention.
• We will be treated as a foreign private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.
• As we are organized under the laws of a Canadian province and certain of our directors and officers reside in Canada or the provinces thereof, it may be difficult for US shareholders to effect service on us to realize on judgments obtained in the United States.
• Similarly, it may be difficult for Canadian investors to enforce civil liabilities against our directors and officers residing outside of Canada.

Future Outlook

Medicus Pharma intends to use the net proceeds from this offering to fund its Phase 2 proof of concept clinical trial for treatment of basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch. We may also use the net proceeds of this offering to expand our exploratory phase 2 clinical trial to a pivotal trial and/or to expand our trials to cover other non-melanoma skin diseases. We will use any remaining net proceeds for general corporate purposes and working capital.

Industry Context

The announcement relates to the biotech/life sciences industry, specifically focusing on the development of novel therapeutics for skin cancer. The company is targeting basal cell carcinoma, a common type of skin cancer, with a minimally invasive treatment option. This aligns with the broader industry trend of developing targeted therapies and innovative drug delivery systems.

Comparison to Industry Standards

• The development of SkinJectTM, a doxorubicin tip-loaded D-MNA for treating basal cell carcinoma, places Medicus Pharma in competition with companies developing topical treatments and drug delivery systems for skin cancers.
• Companies like Castle Biosciences (CSTL) focus on diagnostic and prognostic tests for skin cancers, while Medicus Pharma is developing a therapeutic approach.
• Other companies, such as Sun Pharma and Novartis, have established dermatology portfolios that include treatments for various skin conditions, including skin cancers.
• The success of SkinJectTM will depend on its efficacy, safety, and cost-effectiveness compared to existing treatments like surgical removal, imiquimod, and 5-fluorouracil.
• The company's reliance on microneedle array technology for drug delivery is comparable to other companies exploring transdermal drug delivery systems, such as NanoPass and LTS Lohmann Therapy Systems.
• The company's Phase 1 study results showing complete responses in some participants are promising but need to be confirmed in larger Phase 2 and Phase 3 trials.
• The company's financial position, with an accumulated deficit of approximately US$24.8 million, is typical for early-stage biotech companies focused on drug development.
• The company's ability to secure additional funding and partnerships will be crucial for its long-term success.

Stakeholder Impact

• Shareholders: Potential for increased value if the company is successful in its clinical trials and commercialization efforts.
• Employees: Potential for job growth and career advancement.
• Patients: Potential for a new, minimally invasive treatment option for basal cell carcinoma.
• Underwriters: Opportunity to earn fees and commissions from the offering.

Next Steps

• Obtain Nasdaq listing approval.
• Complete the unit offering.
• Initiate and conduct the Phase 2 clinical trial for SkinJectTM.
• Explore potential expansion of the clinical trial to a pivotal study or other indications.
• Seek additional funding and partnerships to support the company's growth.

Key Dates

Keywords

Medicus Pharma, Nasdaq, unit offering, SkinJect, basal cell carcinoma, warrants, clinical trial, MDCX, biotech, pharmaceutical